Advertisement
News
Advertisement

Boehringer Ingelheim lands good news on HCV treatment

Fri, 04/01/2011 - 9:36am
Mass High Tech: The Journal of New England Technology

Boehringer Ingelheim Corp., a pharmaceutical firm in Ridgefield, Conn., has returned positive antiviral activity results from a Phase 2 clinical trial of its hepatitis C virus (HCV) treatment, BI 201335.

The treatment, a once-daily oral protease inhibitor, showed improvements in both chronic genotype-1 HCV patients with a history of multiple treatments, as well as those new to HCV treatment. The protease inhibitor was tested in conjunction with patients receiving current standard of care, including pegylated interferon and ribavirin.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading